Entourage Health Corp. (ETRGF) Q3 2024 Earnings Call Transcript Summary
Entourage Health Corp. (ETRGF) Q3 2024 Earnings Call Transcript Summary
Net revenue grew 9% year-over-year to $9.5 million, mainly led by growth in the bulk use channel.The following is a summary of the Entourage Health Corp. (ETRGF) Q3 2024 Earnings Call Transcript:
以下是Entourage Health企业(ETRGF) 2024年第三季度业绩会实录摘要:
Financial Performance:
财务表现：
Entourage Health Corp achieved a Q3 2024 total revenue of $13.6 million, an 11% year-over-year increase.
EBITDA increased 70% this quarter and 65% year-over-year, reflecting cost management and operational streamlining.
Net revenue grew 9% year-over-year to $9.5 million, mainly led by growth in the bulk use channel.
Gross profit before changes in fair value increased by 20%, totaling $2.9 million for Q3 2024.
Entourage Health企业取得了2024年第三季度总营业收入1360万美元，同比增长11%。
本季度EBITDA增长了70%，同比增长65%，反映了成本管理和运营优化。
净收入同比增长9%，达到950万美元，主要由批发渠道增长所带动。
在2024年第三季度，公允价值变动前的毛利润增长了20%，达到290万美元。
Business Progress:
业务进展：
Expanded sales channels and product diversification with 23 new SKUs across core brands.
Enhanced production efficiencies by automating pre-rolls, which now produces over 2 million per month.
Plans to launch Chromatica, Sour Grapefruit Haze Live Resin infused pre-rolls, and 20 by 0.5 gram Mega Packs in 2025.
Focusing on the medical cannabis market, specifically targeting veterans and aging populations with innovative patient-centric products.
扩大销售渠道，核心品牌推出23款新SKU，实现产品多元化。
通过自动化卷烟的生产，提高了生产效率，目前每月产量超过200万支。
计划在2025年推出Chromatica、Sour Grapefruit Haze Live Resin注入式卷烟，以及20支0.5克的巨型包装。
专注于医疗大麻市场，特别针对退伍军人和老年人群体，提供创新的以患者为中心的产品。
Opportunities:
机会：
High consumer demand for recently launched innovative formats like infused pre-rolls and value offerings.
Projected growth of Canada's medical cannabis sector, anticipated to surpass $1 billion by 2029.
近期推出的创新格式，如注入式卷烟和优惠产品，受到消费者的高需求。
预计加拿大医疗大麻板块的增长，预计将在2029年超过10亿美元。
Risks:
风险：
Lower medical revenue due to decreased patient renewal rates and reduced basket sizes.
Market forces pushing down sales prices while biomass costs are expected to rise in the short-term.
由于减少的患者续约率和减少的购买篮子大小，医疗营业收入下降。
市场力量推动销售价格下降，而生物质成本预计短期内将上升。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的详情，请参阅投资人关系网站。本文仅供投资者参考，不作任何指引或建议。
译文内容由第三方软件翻译。
